Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company Ltd, today announced a €36 million investment in its Grange Castle facility. The investment will support the expansion of the company’s cell therapy production facility and create approximately 100 new jobs over the next three years.
The biopharmaceutical company is headquartered in Japan and focuses its R&D efforts on four therapeutic areas - Oncology, Rare Genetic and Haematology, Neuroscience, and Gastroenterology (GI). Takeda also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. The commercial scale cell therapy production facility is the first of its kind in Ireland. Following the expansion, the team at Grange Castle will play an important role in supplying European, US and Canadian markets with a cell therapy treatment option for patients.
Welcoming the news yesterday, An Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar said, "I’m really pleased Takeda Ireland is expanding in Grange Castle, creating 100 jobs over the next three years. Our highly skilled workforce is just one of the reasons why Ireland is recognised as a global hub for biopharmaceutical companies like Takeda. I wish them every success with their expansion plans."
Takeda Global Manufacturing & Supply Officer, Thomas Wozniewski added, "The expansion of the cell therapy manufacturing line in Grange Castle will help us to serve more patients worldwide, and it underlines our commitment to Ireland as a key country. With its advanced use of digital technologies, the cell therapy manufacturing lines in Grange Castle are a testimony to our innovation capabilities."